Article
Men who have asymptomatic subclinical vascular disease are more likely to develop erectile dysfunction than men who don't have early stage vascular disease, according to research presented at the American Heart Association's Scientific Sessions 2014.
CHICAGO, Nov. 18, 2014 — Men who have asymptomatic subclinical vascular disease are more likely to develop erectile dysfunction than men who don’t have early stage vascular disease, according to research presented at the American Heart Association’s Scientific Sessions 2014.
“Erectile function can be a window into men’s cardiovascular and overall health,” said David I. Feldman, B.S., lead author and research assistant at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins in Baltimore, Maryland. “Erectile dysfunction and cardiovascular disease commonly coexist.”
Researchers studied 1,862 men without existing heart disease and assessed the relationship between early atherosclerotic plaque development and arterial stiffness and dysfunction with their subsequent self-reporting of erectile dysfunction.
“We looked at which measurement of early vascular disease was the best predictor for erectile dysfunction,” Feldman said. “We also looked at whether those men with multiple abnormalities, such as increased plaque in addition to arterial stiffness and dysfunction, were more likely to also suffer from erectile dysfunction.”
Researchers found:
To improve long-term erectile function and reduce the risk for worsening cardiovascular health, at-risk men should eat a heart-healthy diet, engage in physical activity and avoid smoking, Feldman said.
“Current guidelines recommend exercise stress testing and an ankle-brachial index test for risk assessment in patients with erectile dysfunction,” he said. “Our results suggest a more powerful indicator is direct measurement of coronary plaque through the use of a coronary artery calcium test.”
More research is needed before physicians routinely use coronary artery calcium tests over other noninvasive methods to assess men’s sexual health, Feldman said. And more work needs to be done on how best to prevent erectile dysfunction in those men with confirmed asymptomatic vascular disease.
Researchers excluded men on impotence drugs and couldn’t ensure that all men were free of erectile dysfunction at the study’s baseline examination.
Co-authors are Kevin L. Billups, M.D.; Andrew P. DeFilippis, M.D.; Kanchan Chitaley, Ph.D.; Philip Greenland, M.D.; James H. Stein, M.D.; Matthew J. Budoff, M.D.; Zeina Dardari, M.S.; Roger S. Blumenthal, M.D.; Khurram Nasir, M.D., M.P.H.; and Michael J. Blaha, M.D., M.P.H. Author disclosures are on the abstract.
Additional Resources:
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available atwww.heart.org/corporatefunding.
Note: Actual presentation is 3 p.m.CT, Tuesday, Nov. 18, 2014 (South Hall A2, Core 2).